TP53 mutations are associated with improved survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: results from the MITO16A/MaNGO OV-2 study Article Swipe
Eliana Bignotti
,
Vittorio Simeon
,
Laura Ardighieri
,
Elisabetta Kuhn
,
Sergio Marchini
,
Daniela Califano
,
Sabrina Chiara Cecere
,
Mattia Bugatti
,
Anna Spina
,
Giosuè Scognamiglio
,
Lara Paracchini
,
Daniela Russo
,
Laura Arenare
,
Germana Tognon
,
Domenica Lorusso
,
Luca Beltrame
,
Maurizio D’Incalci
,
Enrico Sartori
,
Andrea De Censi
,
Franco Odicino
,
Francesco Perrone
,
Paolo Chiodini
,
Sandro Pignata
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.5281/zenodo.8138608
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.5281/zenodo.8138608
PURPOSE Bevacizumab (BEV) is considered an effective treatment option for advanced ovarian carcinoma. However, to date, there are no biomarkers that define a BEV-responsive patient subpopulation. METHODS In the context of the MITO16A/MaNGO OV-2 trial, a phase IV study of chemotherapy combined with BEV in first-line treatment of advanced ovarian carcinoma, we evaluated TP53 mutations by next generation sequencing (NGS) and p53 protein expression by immunohistochemistry (IHC) on 202 and 311 cases, respectively. We further correlated NGS and IHC data with clinicopathological characteristics and survival of patients. RESULTS TP53 mutations of unknown function (named unclassified), mostly of the missense type, represented the majority of variants in our population (44.4%) and were associated with a significantly improved overall survival both in univariate (p=0.03, HR=0.43) and multivariate analysis (p=0.012, HR=0.39). Concordance between TP53 mutational analysis and protein expression was 91%. A trend toward improved OS was observed in patients with p53 IHC overexpression (HR=0.70, p=0.15) compared to p53 wild-type patients. CONCLUSION Our results indicate that the presence of unclassified TP53 mutations has favorable prognostic significance in patients with ovarian carcinoma receiving upfront BEV plus chemotherapy. In particular, unclassified missense TP53 mutations characterize a subpopulation of patients with a significant survival advantage, independently of clinicopathological characteristics. Our findings warrant future investigations to confirm the prognostic impact of TP53 mutations in BEV-treated ovarian carcinoma patients and deserve to be assessed for their potential predictive role in future randomized clinical studies.
Related Topics
Concepts
Bevacizumab
Ovarian carcinoma
Oncology
Chemotherapy
Internal medicine
Medicine
Ovarian cancer
Cancer
Metadata
- Type
- dataset
- Language
- en
- Landing Page
- https://doi.org/10.5281/zenodo.8138608
- OA Status
- green
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4393497976
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4393497976Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.5281/zenodo.8138608Digital Object Identifier
- Title
-
TP53 mutations are associated with improved survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: results from the MITO16A/MaNGO OV-2 studyWork title
- Type
-
datasetOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-10-30Full publication date if available
- Authors
-
Eliana Bignotti, Vittorio Simeon, Laura Ardighieri, Elisabetta Kuhn, Sergio Marchini, Daniela Califano, Sabrina Chiara Cecere, Mattia Bugatti, Anna Spina, Giosuè Scognamiglio, Lara Paracchini, Daniela Russo, Laura Arenare, Germana Tognon, Domenica Lorusso, Luca Beltrame, Maurizio D’Incalci, Enrico Sartori, Andrea De Censi, Franco Odicino, Francesco Perrone, Paolo Chiodini, Sandro PignataList of authors in order
- Landing page
-
https://doi.org/10.5281/zenodo.8138608Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.5281/zenodo.8138608Direct OA link when available
- Concepts
-
Bevacizumab, Ovarian carcinoma, Oncology, Chemotherapy, Internal medicine, Medicine, Ovarian cancer, CancerTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4393497976 |
|---|---|
| doi | https://doi.org/10.5281/zenodo.8138608 |
| ids.doi | https://doi.org/10.5281/zenodo.8138608 |
| ids.openalex | https://openalex.org/W4393497976 |
| fwci | |
| type | dataset |
| title | TP53 mutations are associated with improved survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: results from the MITO16A/MaNGO OV-2 study |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10550 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9056000113487244 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2743 |
| topics[0].subfield.display_name | Reproductive Medicine |
| topics[0].display_name | Ovarian cancer diagnosis and treatment |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2777802072 |
| concepts[0].level | 3 |
| concepts[0].score | 0.9118355512619019 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q413299 |
| concepts[0].display_name | Bevacizumab |
| concepts[1].id | https://openalex.org/C3019054536 |
| concepts[1].level | 4 |
| concepts[1].score | 0.6879954934120178 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q172341 |
| concepts[1].display_name | Ovarian carcinoma |
| concepts[2].id | https://openalex.org/C143998085 |
| concepts[2].level | 1 |
| concepts[2].score | 0.6475346684455872 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[2].display_name | Oncology |
| concepts[3].id | https://openalex.org/C2776694085 |
| concepts[3].level | 2 |
| concepts[3].score | 0.6071448922157288 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[3].display_name | Chemotherapy |
| concepts[4].id | https://openalex.org/C126322002 |
| concepts[4].level | 1 |
| concepts[4].score | 0.5609240531921387 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[4].display_name | Internal medicine |
| concepts[5].id | https://openalex.org/C71924100 |
| concepts[5].level | 0 |
| concepts[5].score | 0.5381188988685608 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[5].display_name | Medicine |
| concepts[6].id | https://openalex.org/C2780427987 |
| concepts[6].level | 3 |
| concepts[6].score | 0.5321224331855774 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q172341 |
| concepts[6].display_name | Ovarian cancer |
| concepts[7].id | https://openalex.org/C121608353 |
| concepts[7].level | 2 |
| concepts[7].score | 0.19287213683128357 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[7].display_name | Cancer |
| keywords[0].id | https://openalex.org/keywords/bevacizumab |
| keywords[0].score | 0.9118355512619019 |
| keywords[0].display_name | Bevacizumab |
| keywords[1].id | https://openalex.org/keywords/ovarian-carcinoma |
| keywords[1].score | 0.6879954934120178 |
| keywords[1].display_name | Ovarian carcinoma |
| keywords[2].id | https://openalex.org/keywords/oncology |
| keywords[2].score | 0.6475346684455872 |
| keywords[2].display_name | Oncology |
| keywords[3].id | https://openalex.org/keywords/chemotherapy |
| keywords[3].score | 0.6071448922157288 |
| keywords[3].display_name | Chemotherapy |
| keywords[4].id | https://openalex.org/keywords/internal-medicine |
| keywords[4].score | 0.5609240531921387 |
| keywords[4].display_name | Internal medicine |
| keywords[5].id | https://openalex.org/keywords/medicine |
| keywords[5].score | 0.5381188988685608 |
| keywords[5].display_name | Medicine |
| keywords[6].id | https://openalex.org/keywords/ovarian-cancer |
| keywords[6].score | 0.5321224331855774 |
| keywords[6].display_name | Ovarian cancer |
| keywords[7].id | https://openalex.org/keywords/cancer |
| keywords[7].score | 0.19287213683128357 |
| keywords[7].display_name | Cancer |
| language | en |
| locations[0].id | doi:10.5281/zenodo.8138608 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4306400562 |
| locations[0].source.issn | |
| locations[0].source.type | repository |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | |
| locations[0].source.is_core | False |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Zenodo (CERN European Organization for Nuclear Research) |
| locations[0].source.host_organization | https://openalex.org/I67311998 |
| locations[0].source.host_organization_name | European Organization for Nuclear Research |
| locations[0].source.host_organization_lineage | https://openalex.org/I67311998 |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | |
| locations[0].raw_type | dataset |
| locations[0].license_id | |
| locations[0].is_accepted | False |
| locations[0].is_published | |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.5281/zenodo.8138608 |
| indexed_in | datacite |
| authorships[0].author.id | https://openalex.org/A5054197976 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-6380-6181 |
| authorships[0].author.display_name | Eliana Bignotti |
| authorships[0].countries | IT |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210103289, https://openalex.org/I79940851 |
| authorships[0].affiliations[0].raw_affiliation_string | Angelo Nocivelli' Institute of Molecular Medicine, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy; Division of Obstetrics and Gynecology, ASST Spedali Civili di Brescia, Brescia, Italy |
| authorships[0].institutions[0].id | https://openalex.org/I4210103289 |
| authorships[0].institutions[0].ror | https://ror.org/015rhss58 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210103289 |
| authorships[0].institutions[0].country_code | IT |
| authorships[0].institutions[0].display_name | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia |
| authorships[0].institutions[1].id | https://openalex.org/I79940851 |
| authorships[0].institutions[1].ror | https://ror.org/02q2d2610 |
| authorships[0].institutions[1].type | education |
| authorships[0].institutions[1].lineage | https://openalex.org/I79940851 |
| authorships[0].institutions[1].country_code | IT |
| authorships[0].institutions[1].display_name | University of Brescia |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Eliana Bignotti |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Angelo Nocivelli' Institute of Molecular Medicine, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy; Division of Obstetrics and Gynecology, ASST Spedali Civili di Brescia, Brescia, Italy |
| authorships[1].author.id | https://openalex.org/A5047513866 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-2387-4125 |
| authorships[1].author.display_name | Vittorio Simeon |
| authorships[1].countries | IT |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I197809005 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Mental Health and Public Medicine, Section of Statistics, Università Degli Studi Della Campania Luigi Vanvitelli, 80138 Naples, Italy |
| authorships[1].institutions[0].id | https://openalex.org/I197809005 |
| authorships[1].institutions[0].ror | https://ror.org/02kqnpp86 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I197809005 |
| authorships[1].institutions[0].country_code | IT |
| authorships[1].institutions[0].display_name | University of Campania "Luigi Vanvitelli" |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Vittorio Simeon |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Mental Health and Public Medicine, Section of Statistics, Università Degli Studi Della Campania Luigi Vanvitelli, 80138 Naples, Italy |
| authorships[2].author.id | https://openalex.org/A5030633547 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-6200-9671 |
| authorships[2].author.display_name | Laura Ardighieri |
| authorships[2].countries | IT |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210103289 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Pathology, ASST Spedali Civili di Brescia, Brescia, Italy |
| authorships[2].institutions[0].id | https://openalex.org/I4210103289 |
| authorships[2].institutions[0].ror | https://ror.org/015rhss58 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210103289 |
| authorships[2].institutions[0].country_code | IT |
| authorships[2].institutions[0].display_name | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Laura Ardighieri |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Pathology, ASST Spedali Civili di Brescia, Brescia, Italy |
| authorships[3].author.id | https://openalex.org/A5028627843 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-0620-3821 |
| authorships[3].author.display_name | Elisabetta Kuhn |
| authorships[3].countries | IT |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I189158943, https://openalex.org/I2803066834 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Biomedical Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy; Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Pathology Unit, 20122 Milan, Italy |
| authorships[3].institutions[0].id | https://openalex.org/I2803066834 |
| authorships[3].institutions[0].ror | https://ror.org/016zn0y21 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I2803066834, https://openalex.org/I4210153126 |
| authorships[3].institutions[0].country_code | IT |
| authorships[3].institutions[0].display_name | Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico |
| authorships[3].institutions[1].id | https://openalex.org/I189158943 |
| authorships[3].institutions[1].ror | https://ror.org/00wjc7c48 |
| authorships[3].institutions[1].type | education |
| authorships[3].institutions[1].lineage | https://openalex.org/I189158943 |
| authorships[3].institutions[1].country_code | IT |
| authorships[3].institutions[1].display_name | University of Milan |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Elisabetta Kuhn |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Biomedical Surgical and Dental Sciences, University of Milan, 20122 Milan, Italy; Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Pathology Unit, 20122 Milan, Italy |
| authorships[4].author.id | https://openalex.org/A5069986334 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-1783-7651 |
| authorships[4].author.display_name | Sergio Marchini |
| authorships[4].countries | IT |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I4210163047 |
| authorships[4].affiliations[0].raw_affiliation_string | IRCCS Humanitas Research Hospital, Molecular Pharmacology Lab, Rozzano, Italy |
| authorships[4].institutions[0].id | https://openalex.org/I4210163047 |
| authorships[4].institutions[0].ror | https://ror.org/05d538656 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I4210153126, https://openalex.org/I4210163047 |
| authorships[4].institutions[0].country_code | IT |
| authorships[4].institutions[0].display_name | IRCCS Humanitas Research Hospital |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Sergio Marchini |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | IRCCS Humanitas Research Hospital, Molecular Pharmacology Lab, Rozzano, Italy |
| authorships[5].author.id | https://openalex.org/A5040899290 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-6945-3209 |
| authorships[5].author.display_name | Daniela Califano |
| authorships[5].countries | IT |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210141868 |
| authorships[5].affiliations[0].raw_affiliation_string | Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, 80131 Naples, Italy |
| authorships[5].institutions[0].id | https://openalex.org/I4210141868 |
| authorships[5].institutions[0].ror | https://ror.org/0506y2b23 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210141868, https://openalex.org/I4210153126 |
| authorships[5].institutions[0].country_code | IT |
| authorships[5].institutions[0].display_name | Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Daniela Califano |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, 80131 Naples, Italy |
| authorships[6].author.id | https://openalex.org/A5044888208 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-7915-1623 |
| authorships[6].author.display_name | Sabrina Chiara Cecere |
| authorships[6].countries | IT |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210141868 |
| authorships[6].affiliations[0].raw_affiliation_string | Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples, Italy. |
| authorships[6].institutions[0].id | https://openalex.org/I4210141868 |
| authorships[6].institutions[0].ror | https://ror.org/0506y2b23 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210141868, https://openalex.org/I4210153126 |
| authorships[6].institutions[0].country_code | IT |
| authorships[6].institutions[0].display_name | Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Sabrina Chiara Cecere |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples, Italy. |
| authorships[7].author.id | https://openalex.org/A5006833404 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-5090-8338 |
| authorships[7].author.display_name | Mattia Bugatti |
| authorships[7].countries | IT |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210103289 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Pathology, ASST Spedali Civili di Brescia, Brescia, Italy |
| authorships[7].institutions[0].id | https://openalex.org/I4210103289 |
| authorships[7].institutions[0].ror | https://ror.org/015rhss58 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210103289 |
| authorships[7].institutions[0].country_code | IT |
| authorships[7].institutions[0].display_name | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Mattia Bugatti |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Pathology, ASST Spedali Civili di Brescia, Brescia, Italy |
| authorships[8].author.id | https://openalex.org/A5066026550 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-4726-9299 |
| authorships[8].author.display_name | Anna Spina |
| authorships[8].countries | IT |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I4210141868 |
| authorships[8].affiliations[0].raw_affiliation_string | Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, 80131 Naples, Italy |
| authorships[8].institutions[0].id | https://openalex.org/I4210141868 |
| authorships[8].institutions[0].ror | https://ror.org/0506y2b23 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210141868, https://openalex.org/I4210153126 |
| authorships[8].institutions[0].country_code | IT |
| authorships[8].institutions[0].display_name | Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Anna Spina |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, 80131 Naples, Italy |
| authorships[9].author.id | https://openalex.org/A5049219849 |
| authorships[9].author.orcid | https://orcid.org/0000-0003-4376-111X |
| authorships[9].author.display_name | Giosuè Scognamiglio |
| authorships[9].countries | IT |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210141868 |
| authorships[9].affiliations[0].raw_affiliation_string | Pathology Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, 80131 Naples, Italy. |
| authorships[9].institutions[0].id | https://openalex.org/I4210141868 |
| authorships[9].institutions[0].ror | https://ror.org/0506y2b23 |
| authorships[9].institutions[0].type | healthcare |
| authorships[9].institutions[0].lineage | https://openalex.org/I4210141868, https://openalex.org/I4210153126 |
| authorships[9].institutions[0].country_code | IT |
| authorships[9].institutions[0].display_name | Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Giosuè Scognamiglio |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Pathology Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, 80131 Naples, Italy. |
| authorships[10].author.id | https://openalex.org/A5020635291 |
| authorships[10].author.orcid | https://orcid.org/0000-0003-1832-5471 |
| authorships[10].author.display_name | Lara Paracchini |
| authorships[10].countries | IT |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I4210163047 |
| authorships[10].affiliations[0].raw_affiliation_string | IRCCS Humanitas Research Hospital, Molecular Pharmacology Lab, Rozzano, Italy |
| authorships[10].institutions[0].id | https://openalex.org/I4210163047 |
| authorships[10].institutions[0].ror | https://ror.org/05d538656 |
| authorships[10].institutions[0].type | healthcare |
| authorships[10].institutions[0].lineage | https://openalex.org/I4210153126, https://openalex.org/I4210163047 |
| authorships[10].institutions[0].country_code | IT |
| authorships[10].institutions[0].display_name | IRCCS Humanitas Research Hospital |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Lara Paracchini |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | IRCCS Humanitas Research Hospital, Molecular Pharmacology Lab, Rozzano, Italy |
| authorships[11].author.id | https://openalex.org/A5079704027 |
| authorships[11].author.orcid | https://orcid.org/0000-0001-9471-1935 |
| authorships[11].author.display_name | Daniela Russo |
| authorships[11].countries | IT |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210141868 |
| authorships[11].affiliations[0].raw_affiliation_string | Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, 80131 Naples, Italy |
| authorships[11].institutions[0].id | https://openalex.org/I4210141868 |
| authorships[11].institutions[0].ror | https://ror.org/0506y2b23 |
| authorships[11].institutions[0].type | healthcare |
| authorships[11].institutions[0].lineage | https://openalex.org/I4210141868, https://openalex.org/I4210153126 |
| authorships[11].institutions[0].country_code | IT |
| authorships[11].institutions[0].display_name | Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Daniela Russo |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, 80131 Naples, Italy |
| authorships[12].author.id | https://openalex.org/A5023024840 |
| authorships[12].author.orcid | https://orcid.org/0000-0001-7100-4517 |
| authorships[12].author.display_name | Laura Arenare |
| authorships[12].countries | IT |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I4210141868 |
| authorships[12].affiliations[0].raw_affiliation_string | Clinical Trials Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, 80131 Naples, Italy |
| authorships[12].institutions[0].id | https://openalex.org/I4210141868 |
| authorships[12].institutions[0].ror | https://ror.org/0506y2b23 |
| authorships[12].institutions[0].type | healthcare |
| authorships[12].institutions[0].lineage | https://openalex.org/I4210141868, https://openalex.org/I4210153126 |
| authorships[12].institutions[0].country_code | IT |
| authorships[12].institutions[0].display_name | Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Laura Arenare |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Clinical Trials Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, 80131 Naples, Italy |
| authorships[13].author.id | https://openalex.org/A5040915026 |
| authorships[13].author.orcid | https://orcid.org/0000-0003-3935-4992 |
| authorships[13].author.display_name | Germana Tognon |
| authorships[13].countries | IT |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I4210103289 |
| authorships[13].affiliations[0].raw_affiliation_string | Division of Obstetrics and Gynecology, ASST Spedali Civili di Brescia, Brescia, Italy |
| authorships[13].institutions[0].id | https://openalex.org/I4210103289 |
| authorships[13].institutions[0].ror | https://ror.org/015rhss58 |
| authorships[13].institutions[0].type | healthcare |
| authorships[13].institutions[0].lineage | https://openalex.org/I4210103289 |
| authorships[13].institutions[0].country_code | IT |
| authorships[13].institutions[0].display_name | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Germana Tognon |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Division of Obstetrics and Gynecology, ASST Spedali Civili di Brescia, Brescia, Italy |
| authorships[14].author.id | https://openalex.org/A5061939825 |
| authorships[14].author.orcid | https://orcid.org/0000-0003-0981-0598 |
| authorships[14].author.display_name | Domenica Lorusso |
| authorships[14].countries | IT |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I2802557943 |
| authorships[14].affiliations[0].raw_affiliation_string | Department of Life Science and Public Health, Catholic University of Sacred Heart Largo Agostino Gemelli, and Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy |
| authorships[14].institutions[0].id | https://openalex.org/I2802557943 |
| authorships[14].institutions[0].ror | https://ror.org/00rg70c39 |
| authorships[14].institutions[0].type | healthcare |
| authorships[14].institutions[0].lineage | https://openalex.org/I2802557943 |
| authorships[14].institutions[0].country_code | IT |
| authorships[14].institutions[0].display_name | Agostino Gemelli University Polyclinic |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Domenica Lorusso |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Department of Life Science and Public Health, Catholic University of Sacred Heart Largo Agostino Gemelli, and Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy |
| authorships[15].author.id | https://openalex.org/A5039120460 |
| authorships[15].author.orcid | https://orcid.org/0000-0003-3631-6544 |
| authorships[15].author.display_name | Luca Beltrame |
| authorships[15].countries | IT |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I4210163047 |
| authorships[15].affiliations[0].raw_affiliation_string | IRCCS Humanitas Research Hospital, Molecular Pharmacology Lab, Rozzano, Italy |
| authorships[15].institutions[0].id | https://openalex.org/I4210163047 |
| authorships[15].institutions[0].ror | https://ror.org/05d538656 |
| authorships[15].institutions[0].type | healthcare |
| authorships[15].institutions[0].lineage | https://openalex.org/I4210153126, https://openalex.org/I4210163047 |
| authorships[15].institutions[0].country_code | IT |
| authorships[15].institutions[0].display_name | IRCCS Humanitas Research Hospital |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Luca Beltrame |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | IRCCS Humanitas Research Hospital, Molecular Pharmacology Lab, Rozzano, Italy |
| authorships[16].author.id | https://openalex.org/A5055703421 |
| authorships[16].author.orcid | https://orcid.org/0000-0001-8784-1360 |
| authorships[16].author.display_name | Maurizio D’Incalci |
| authorships[16].countries | IT |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I4210163047 |
| authorships[16].affiliations[0].raw_affiliation_string | IRCCS Humanitas Research Hospital, Molecular Pharmacology Lab, Rozzano, Italy |
| authorships[16].institutions[0].id | https://openalex.org/I4210163047 |
| authorships[16].institutions[0].ror | https://ror.org/05d538656 |
| authorships[16].institutions[0].type | healthcare |
| authorships[16].institutions[0].lineage | https://openalex.org/I4210153126, https://openalex.org/I4210163047 |
| authorships[16].institutions[0].country_code | IT |
| authorships[16].institutions[0].display_name | IRCCS Humanitas Research Hospital |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Maurizio D'Incalci |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | IRCCS Humanitas Research Hospital, Molecular Pharmacology Lab, Rozzano, Italy |
| authorships[17].author.id | https://openalex.org/A5074577188 |
| authorships[17].author.orcid | https://orcid.org/0000-0003-4076-303X |
| authorships[17].author.display_name | Enrico Sartori |
| authorships[17].countries | IT |
| authorships[17].affiliations[0].institution_ids | https://openalex.org/I4210103289, https://openalex.org/I79940851 |
| authorships[17].affiliations[0].raw_affiliation_string | Division of Obstetrics and Gynecology, ASST Spedali Civili di Brescia, Brescia, Italy ; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy |
| authorships[17].institutions[0].id | https://openalex.org/I4210103289 |
| authorships[17].institutions[0].ror | https://ror.org/015rhss58 |
| authorships[17].institutions[0].type | healthcare |
| authorships[17].institutions[0].lineage | https://openalex.org/I4210103289 |
| authorships[17].institutions[0].country_code | IT |
| authorships[17].institutions[0].display_name | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia |
| authorships[17].institutions[1].id | https://openalex.org/I79940851 |
| authorships[17].institutions[1].ror | https://ror.org/02q2d2610 |
| authorships[17].institutions[1].type | education |
| authorships[17].institutions[1].lineage | https://openalex.org/I79940851 |
| authorships[17].institutions[1].country_code | IT |
| authorships[17].institutions[1].display_name | University of Brescia |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Enrico Sartori |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | Division of Obstetrics and Gynecology, ASST Spedali Civili di Brescia, Brescia, Italy ; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy |
| authorships[18].author.id | https://openalex.org/A5110666941 |
| authorships[18].author.orcid | |
| authorships[18].author.display_name | Andrea De Censi |
| authorships[18].countries | IT |
| authorships[18].affiliations[0].institution_ids | https://openalex.org/I3018768319 |
| authorships[18].affiliations[0].raw_affiliation_string | Oncologia Medica, Ospedali Galliera, Genoa, Italy |
| authorships[18].institutions[0].id | https://openalex.org/I3018768319 |
| authorships[18].institutions[0].ror | https://ror.org/05bs6ak67 |
| authorships[18].institutions[0].type | healthcare |
| authorships[18].institutions[0].lineage | https://openalex.org/I3018768319 |
| authorships[18].institutions[0].country_code | IT |
| authorships[18].institutions[0].display_name | Ente Ospedaliero Ospedali Galliera |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Andrea De Censi |
| authorships[18].is_corresponding | False |
| authorships[18].raw_affiliation_strings | Oncologia Medica, Ospedali Galliera, Genoa, Italy |
| authorships[19].author.id | https://openalex.org/A5057508704 |
| authorships[19].author.orcid | https://orcid.org/0000-0001-8870-4739 |
| authorships[19].author.display_name | Franco Odicino |
| authorships[19].countries | IT |
| authorships[19].affiliations[0].institution_ids | https://openalex.org/I4210103289, https://openalex.org/I79940851 |
| authorships[19].affiliations[0].raw_affiliation_string | Division of Obstetrics and Gynecology, ASST Spedali Civili di Brescia, Brescia, Italy ; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy |
| authorships[19].institutions[0].id | https://openalex.org/I4210103289 |
| authorships[19].institutions[0].ror | https://ror.org/015rhss58 |
| authorships[19].institutions[0].type | healthcare |
| authorships[19].institutions[0].lineage | https://openalex.org/I4210103289 |
| authorships[19].institutions[0].country_code | IT |
| authorships[19].institutions[0].display_name | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia |
| authorships[19].institutions[1].id | https://openalex.org/I79940851 |
| authorships[19].institutions[1].ror | https://ror.org/02q2d2610 |
| authorships[19].institutions[1].type | education |
| authorships[19].institutions[1].lineage | https://openalex.org/I79940851 |
| authorships[19].institutions[1].country_code | IT |
| authorships[19].institutions[1].display_name | University of Brescia |
| authorships[19].author_position | middle |
| authorships[19].raw_author_name | Franco Odicino |
| authorships[19].is_corresponding | False |
| authorships[19].raw_affiliation_strings | Division of Obstetrics and Gynecology, ASST Spedali Civili di Brescia, Brescia, Italy ; Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy |
| authorships[20].author.id | https://openalex.org/A5102804100 |
| authorships[20].author.orcid | https://orcid.org/0000-0002-9738-0526 |
| authorships[20].author.display_name | Francesco Perrone |
| authorships[20].countries | IT |
| authorships[20].affiliations[0].institution_ids | https://openalex.org/I4210141868 |
| authorships[20].affiliations[0].raw_affiliation_string | Clinical Trials Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, 80131 Naples, Italy |
| authorships[20].institutions[0].id | https://openalex.org/I4210141868 |
| authorships[20].institutions[0].ror | https://ror.org/0506y2b23 |
| authorships[20].institutions[0].type | healthcare |
| authorships[20].institutions[0].lineage | https://openalex.org/I4210141868, https://openalex.org/I4210153126 |
| authorships[20].institutions[0].country_code | IT |
| authorships[20].institutions[0].display_name | Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" |
| authorships[20].author_position | middle |
| authorships[20].raw_author_name | Francesco Perrone |
| authorships[20].is_corresponding | False |
| authorships[20].raw_affiliation_strings | Clinical Trials Unit, Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, 80131 Naples, Italy |
| authorships[21].author.id | https://openalex.org/A5048229494 |
| authorships[21].author.orcid | https://orcid.org/0000-0003-0139-2264 |
| authorships[21].author.display_name | Paolo Chiodini |
| authorships[21].countries | IT |
| authorships[21].affiliations[0].institution_ids | https://openalex.org/I197809005 |
| authorships[21].affiliations[0].raw_affiliation_string | Department of Mental Health and Public Medicine, Section of Statistics, Università Degli Studi Della Campania Luigi Vanvitelli, 80138 Naples, Italy |
| authorships[21].institutions[0].id | https://openalex.org/I197809005 |
| authorships[21].institutions[0].ror | https://ror.org/02kqnpp86 |
| authorships[21].institutions[0].type | education |
| authorships[21].institutions[0].lineage | https://openalex.org/I197809005 |
| authorships[21].institutions[0].country_code | IT |
| authorships[21].institutions[0].display_name | University of Campania "Luigi Vanvitelli" |
| authorships[21].author_position | middle |
| authorships[21].raw_author_name | Paolo Chiodini |
| authorships[21].is_corresponding | False |
| authorships[21].raw_affiliation_strings | Department of Mental Health and Public Medicine, Section of Statistics, Università Degli Studi Della Campania Luigi Vanvitelli, 80138 Naples, Italy |
| authorships[22].author.id | https://openalex.org/A5083659627 |
| authorships[22].author.orcid | https://orcid.org/0000-0002-8836-2633 |
| authorships[22].author.display_name | Sandro Pignata |
| authorships[22].countries | IT |
| authorships[22].affiliations[0].institution_ids | https://openalex.org/I4210141868 |
| authorships[22].affiliations[0].raw_affiliation_string | Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples, Italy. |
| authorships[22].institutions[0].id | https://openalex.org/I4210141868 |
| authorships[22].institutions[0].ror | https://ror.org/0506y2b23 |
| authorships[22].institutions[0].type | healthcare |
| authorships[22].institutions[0].lineage | https://openalex.org/I4210141868, https://openalex.org/I4210153126 |
| authorships[22].institutions[0].country_code | IT |
| authorships[22].institutions[0].display_name | Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" |
| authorships[22].author_position | last |
| authorships[22].raw_author_name | Sandro Pignata |
| authorships[22].is_corresponding | False |
| authorships[22].raw_affiliation_strings | Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples, Italy. |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.5281/zenodo.8138608 |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | TP53 mutations are associated with improved survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: results from the MITO16A/MaNGO OV-2 study |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T06:51:31.235846 |
| primary_topic.id | https://openalex.org/T10550 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9056000113487244 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2743 |
| primary_topic.subfield.display_name | Reproductive Medicine |
| primary_topic.display_name | Ovarian cancer diagnosis and treatment |
| related_works | https://openalex.org/W4225091507, https://openalex.org/W2037317309, https://openalex.org/W2733092439, https://openalex.org/W2051540233, https://openalex.org/W2090201823, https://openalex.org/W2007136227, https://openalex.org/W2010599540, https://openalex.org/W4253708213, https://openalex.org/W3015833062, https://openalex.org/W2353600203 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.5281/zenodo.8138608 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4306400562 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Zenodo (CERN European Organization for Nuclear Research) |
| best_oa_location.source.host_organization | https://openalex.org/I67311998 |
| best_oa_location.source.host_organization_name | European Organization for Nuclear Research |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I67311998 |
| best_oa_location.license | |
| best_oa_location.pdf_url | |
| best_oa_location.version | |
| best_oa_location.raw_type | dataset |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | False |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.5281/zenodo.8138608 |
| primary_location.id | doi:10.5281/zenodo.8138608 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4306400562 |
| primary_location.source.issn | |
| primary_location.source.type | repository |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | |
| primary_location.source.is_core | False |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Zenodo (CERN European Organization for Nuclear Research) |
| primary_location.source.host_organization | https://openalex.org/I67311998 |
| primary_location.source.host_organization_name | European Organization for Nuclear Research |
| primary_location.source.host_organization_lineage | https://openalex.org/I67311998 |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | |
| primary_location.raw_type | dataset |
| primary_location.license_id | |
| primary_location.is_accepted | False |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.5281/zenodo.8138608 |
| publication_date | 2023-10-30 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.A | 138 |
| abstract_inverted_index.a | 22, 35, 113, 190, 195 |
| abstract_inverted_index.IV | 37 |
| abstract_inverted_index.In | 27, 183 |
| abstract_inverted_index.OS | 142 |
| abstract_inverted_index.We | 73 |
| abstract_inverted_index.an | 5 |
| abstract_inverted_index.be | 224 |
| abstract_inverted_index.by | 55, 64 |
| abstract_inverted_index.in | 44, 105, 119, 145, 173, 216, 231 |
| abstract_inverted_index.is | 3 |
| abstract_inverted_index.no | 18 |
| abstract_inverted_index.of | 30, 39, 47, 85, 90, 96, 103, 165, 192, 200, 213 |
| abstract_inverted_index.on | 67 |
| abstract_inverted_index.to | 14, 154, 208, 223 |
| abstract_inverted_index.we | 51 |
| abstract_inverted_index.202 | 68 |
| abstract_inverted_index.311 | 70 |
| abstract_inverted_index.BEV | 43, 180 |
| abstract_inverted_index.IHC | 78, 149 |
| abstract_inverted_index.NGS | 76 |
| abstract_inverted_index.Our | 203 |
| abstract_inverted_index.and | 60, 69, 77, 83, 109, 123, 133, 221 |
| abstract_inverted_index.are | 17 |
| abstract_inverted_index.for | 9, 226 |
| abstract_inverted_index.has | 169 |
| abstract_inverted_index.our | 106 |
| abstract_inverted_index.p53 | 61, 148, 155 |
| abstract_inverted_index.the | 28, 31, 97, 101, 163, 210 |
| abstract_inverted_index.was | 136, 143 |
| abstract_inverted_index.91%. | 137 |
| abstract_inverted_index.OV-2 | 33 |
| abstract_inverted_index.both | 118 |
| abstract_inverted_index.data | 79 |
| abstract_inverted_index.next | 56 |
| abstract_inverted_index.plus | 181 |
| abstract_inverted_index.role | 230 |
| abstract_inverted_index.that | 20, 162 |
| abstract_inverted_index.were | 110 |
| abstract_inverted_index.with | 42, 80, 112, 147, 175, 194 |
| abstract_inverted_index.(BEV) | 2 |
| abstract_inverted_index.(IHC) | 66 |
| abstract_inverted_index.(NGS) | 59 |
| abstract_inverted_index.date, | 15 |
| abstract_inverted_index.phase | 36 |
| abstract_inverted_index.study | 38 |
| abstract_inverted_index.their | 227 |
| abstract_inverted_index.there | 16 |
| abstract_inverted_index.trend | 139 |
| abstract_inverted_index.type, | 99 |
| abstract_inverted_index.(named | 93 |
| abstract_inverted_index.cases, | 71 |
| abstract_inverted_index.define | 21 |
| abstract_inverted_index.future | 206, 232 |
| abstract_inverted_index.impact | 212 |
| abstract_inverted_index.mostly | 95 |
| abstract_inverted_index.option | 8 |
| abstract_inverted_index.toward | 140 |
| abstract_inverted_index.trial, | 34 |
| abstract_inverted_index.(44.4%) | 108 |
| abstract_inverted_index.between | 129 |
| abstract_inverted_index.confirm | 209 |
| abstract_inverted_index.context | 29 |
| abstract_inverted_index.deserve | 222 |
| abstract_inverted_index.further | 74 |
| abstract_inverted_index.ovarian | 11, 49, 176, 218 |
| abstract_inverted_index.overall | 116 |
| abstract_inverted_index.p=0.15) | 152 |
| abstract_inverted_index.patient | 24 |
| abstract_inverted_index.protein | 62, 134 |
| abstract_inverted_index.results | 160 |
| abstract_inverted_index.unknown | 91 |
| abstract_inverted_index.upfront | 179 |
| abstract_inverted_index.warrant | 205 |
| abstract_inverted_index.(p=0.03, | 121 |
| abstract_inverted_index.<em>TP53 | 130, 214 |
| abstract_inverted_index.HR=0.43) | 122 |
| abstract_inverted_index.However, | 13 |
| abstract_inverted_index.advanced | 10, 48 |
| abstract_inverted_index.analysis | 125, 132 |
| abstract_inverted_index.assessed | 225 |
| abstract_inverted_index.clinical | 234 |
| abstract_inverted_index.combined | 41 |
| abstract_inverted_index.compared | 153 |
| abstract_inverted_index.findings | 204 |
| abstract_inverted_index.function | 92 |
| abstract_inverted_index.improved | 115, 141 |
| abstract_inverted_index.indicate | 161 |
| abstract_inverted_index.majority | 102 |
| abstract_inverted_index.missense | 98, 186 |
| abstract_inverted_index.observed | 144 |
| abstract_inverted_index.patients | 146, 174, 193, 220 |
| abstract_inverted_index.presence | 164 |
| abstract_inverted_index.studies. | 235 |
| abstract_inverted_index.survival | 84, 117, 197 |
| abstract_inverted_index.variants | 104 |
| abstract_inverted_index.(HR=0.70, | 151 |
| abstract_inverted_index.(p=0.012, | 126 |
| abstract_inverted_index.HR=0.39). | 127 |
| abstract_inverted_index.carcinoma | 177, 219 |
| abstract_inverted_index.effective | 6 |
| abstract_inverted_index.evaluated | 52 |
| abstract_inverted_index.favorable | 170 |
| abstract_inverted_index.mutations | 54, 89, 168, 188 |
| abstract_inverted_index.patients. | 86, 157 |
| abstract_inverted_index.potential | 228 |
| abstract_inverted_index.receiving | 178 |
| abstract_inverted_index.treatment | 7, 46 |
| abstract_inverted_index.wild-type | 156 |
| abstract_inverted_index.advantage, | 198 |
| abstract_inverted_index.associated | 111 |
| abstract_inverted_index.biomarkers | 19 |
| abstract_inverted_index.carcinoma, | 50 |
| abstract_inverted_index.carcinoma. | 12 |
| abstract_inverted_index.considered | 4 |
| abstract_inverted_index.correlated | 75 |
| abstract_inverted_index.expression | 63, 135 |
| abstract_inverted_index.first-line | 45 |
| abstract_inverted_index.generation | 57 |
| abstract_inverted_index.population | 107 |
| abstract_inverted_index.predictive | 229 |
| abstract_inverted_index.prognostic | 171, 211 |
| abstract_inverted_index.randomized | 233 |
| abstract_inverted_index.sequencing | 58 |
| abstract_inverted_index.univariate | 120 |
| abstract_inverted_index.BEV-treated | 217 |
| abstract_inverted_index.Bevacizumab | 1 |
| abstract_inverted_index.Concordance | 128 |
| abstract_inverted_index.particular, | 184 |
| abstract_inverted_index.represented | 100 |
| abstract_inverted_index.significant | 196 |
| abstract_inverted_index.</strong>Our | 159 |
| abstract_inverted_index.characterize | 189 |
| abstract_inverted_index.chemotherapy | 40 |
| abstract_inverted_index.multivariate | 124 |
| abstract_inverted_index.significance | 172 |
| abstract_inverted_index.unclassified | 166, 185 |
| abstract_inverted_index.<em>TP53</em> | 53, 88, 167, 187 |
| abstract_inverted_index.MITO16A/MaNGO | 32 |
| abstract_inverted_index.chemotherapy. | 182 |
| abstract_inverted_index.independently | 199 |
| abstract_inverted_index.respectively. | 72 |
| abstract_inverted_index.significantly | 114 |
| abstract_inverted_index.subpopulation | 191 |
| abstract_inverted_index.</em>mutations | 215 |
| abstract_inverted_index.BEV-responsive | 23 |
| abstract_inverted_index.investigations | 207 |
| abstract_inverted_index.overexpression | 150 |
| abstract_inverted_index.subpopulation. | 25 |
| abstract_inverted_index.unclassified), | 94 |
| abstract_inverted_index.</em>mutational | 131 |
| abstract_inverted_index.characteristics | 82 |
| abstract_inverted_index.characteristics. | 202 |
| abstract_inverted_index.<strong>CONCLUSION | 158 |
| abstract_inverted_index.clinicopathological | 81, 201 |
| abstract_inverted_index.immunohistochemistry | 65 |
| abstract_inverted_index.<strong>METHODS</strong> | 26 |
| abstract_inverted_index.<strong>PURPOSE</strong> | 0 |
| abstract_inverted_index.<strong>RESULTS</strong> | 87 |
| cited_by_percentile_year | |
| countries_distinct_count | 1 |
| institutions_distinct_count | 23 |
| citation_normalized_percentile |